The two turbinoplasty techniques diverge at a year, not at a month

Design

prospective randomised controlled trial with blinded outcome assessors, 12-month follow-up

Population

44 patients with inferior turbinate hypertrophy and persistent nasal obstruction after medical treatment; 21 medial flap, 23 coblation-assisted

Primary outcome

NOSE scale and visual analogue score for nasal obstruction at 1, 3, 6 and 12 months

Effect

at 12 months NOSE 18.5 vs 34.5 (P=0.027) and VAS 2.2 vs 4.0 (P=0.043) favouring medial flap; greater turbinate size reduction (P<0.001) and less crusting

Inferior turbinate hypertrophy that has failed medical management is one of the commonest reasons for elective nasal surgery, and the choice of technique is usually made on training and equipment rather than evidence. This prospective randomised trial assigned surgical candidates to medial flap turbinoplasty or coblation-assisted turbinoplasty, with outcome examiners blinded to the technique, and followed them with NOSE and visual analogue scores at 1, 3, 6 and 12 months.

Forty-four patients completed the study, 21 in the medial flap arm and 23 in the coblation arm. Both techniques produced substantial symptom improvement at every timepoint (P<0.0001). Early outcomes were similar - which is the part that matters for how this result has been missed until now. At 12 months the medial flap group was clearly better: NOSE 18.5 against 34.5 (P=0.027) and visual analogue score 2.2 against 4.0 (P=0.043). Endoscopic turbinate size reduction was greater (P<0.001) and postoperative crusting significantly less. Pain scores and recovery times did not differ.

The practical reading is about follow-up as much as about technique. A trial that stopped at three months would have concluded the two were equivalent, and most surgeons see these patients once at six weeks and never again. What this supports is preferring the medial flap in appropriately selected patients, and auditing your own turbinate outcomes at a year rather than at the postoperative visit. Forty-four patients is a small trial, and the confidence in a 16-point NOSE difference from a sample this size is limited.

• Prefer medial flap turbinoplasty where the anatomy and your training allow - the advantage appears at 12 months, not before.
• Do not conclude equivalence from an early postoperative visit; the arms were indistinguishable at 1 and 3 months.
• Warn coblation patients about crusting specifically; it was significantly more common in that arm.
• Book a 12-month review, or at least a telephone NOSE score, if you want to know what your surgery achieved.
• This is 44 patients at a single department - a reason to prefer a technique, not to abandon the alternative.

The statistics, in plain English

With 21 and 23 patients per arm, a P value of 0.027 sits close enough to the threshold that a few patients falling differently would change it, and no confidence intervals are reported for the between-group differences - so the direction of the finding is more secure than its size. The blinding of outcome examiners is what makes the endoscopic and symptom comparisons credible in a trial where the surgeon obviously knows which operation was done. Both arms improving at P<0.0001 from baseline tells you the operations work; it says nothing about which is better, and conflating the two is the commonest misreading of a trial shaped like this.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.